Laurent MOREL

Resume

Laurent MORELprofile picture None

Research

None

Publications

  • 2021
  • 2020
  • 2019
  • 2018
  • 2016
  • 2015
    • Z. Ouedraogo, M. Muller-Barthelemy, J. Kemeny, V. Dedieu, J. Biau, T. Khalil, L. Raoelfils, A. Granzotto, B. Pereira, C. Beaudoin, I. Guissou, M. Berger, L. Morel, E. Chautard and P. Verrelle, “STAT3 serine 727 phosphorylation: a relevant target to radiosensitize human glioblastoma.”, Brain pathology (Zurich, Switzerland), 2015.
  • 2014
    • H. Ibrahim, C. Gibard, C. Hesling, R. Guillot, L. Morel, A. Gautier and F. Cisnetti, “'Auto-click' functionalization for diversified copper(I) and gold(I) NHCs.”, Dalton trans., vol. 43 (19) , pp. 6981–9, 2014.
    • G. Loubeau, R. Boudra, S. Maquaire, C. Lours-Calet, C. Beaudoin, P. Verrelle and L. Morel, “NPM1 Silencing Reduces Tumour Growth and MAPK Signalling in Prostate Cancer Cells.”, PLoS ONE, vol. 9 (5) , pp. e96293, 2014.
    • B. Bayala, I. Bassole, C. Gnoula, R. Nebie, A. Yonli, L. Morel, G. Figueredo, J. Nikiema, JM. Lobaccaro and J. Simpore, “Chemical composition, antioxidant, anti-inflammatory and anti-proliferative activities of essential oils of plants from Burkina Faso.”, PLoS ONE, vol. 9 (3) , pp. e92122, 2014.
    • B. Bayala, I. Bassole, R. Scifo, C. Gnoula, L. Morel, JM. Lobaccaro and J. Simpore, “Anticancer activity of essential oils and their chemical components - a review.”, Am J Cancer Res, vol. 4 (6) , pp. 591–607, 2014.
  • 2013
    • C. Gaillard, P. Adumeau, J. Canet, A. Gautier, D. Boyer, C. Beaudoin, C. Hesling, L. Morel and R. Mahiou, “Monodisperse silica nanoparticles doped with dipicolinic acid-based luminescent lanthanide(iii) complexes for bio-labelling.”, Journal of materials chemistry. B, vol. 1 (34) , pp. 4306–4312, 2013.
  • 2012
    • E. Viennois, T. Esposito, J. Dufour, A. Pommier, S. Fabre, J. Kemeny, L. Guy, L. Morel, JM. Lobaccaro and S. Baron, “Lxralpha regulates the androgen response in prostate epithelium.”, Endocrinology, vol. 153 (7) , pp. 3211–23, 2012.
    • L. Eloy, A. Jarrousse, M. Teyssot, A. Gautier, L. Morel, C. Jolivalt, T. Cresteil and S. Roland, “Anticancer activity of silver-N-heterocyclic carbene complexes: caspase-independent induction of apoptosis via mitochondrial apoptosis-inducing factor (AIF).”, ChemMedChem, vol. 7 (5) , pp. 805–14, 2012.
  • 2011
    • E. Viennois, K. Mouzat, J. Dufour, L. Morel, JM. Lobaccaro and S. Baron, “Selective liver X receptor modulators (SLiMs): what use in human health?”, Molecular and cellular endocrinology, vol. 351 (2) , pp. 129–41, 2011.
    • G. Alves, L. Morel, M. El-Ghozzi, D. Avignant, B. Legeret, L. Nauton, F. Cisnetti and A. Gautier, “A platinum Chugaev carbene complex as a potent anticancer agent.”, Chemical communications (Cambridge, England), vol. 47 (27) , pp. 7830–2, 2011.
  • 2010
    • E. Chautard, G. Loubeau, A. Tchirkov, J. Chassagne, C. Vermot-Desroches, L. Morel and P. Verrelle, “Akt signaling pathway: a target for radiosensitizing human malignant glioma.”, Neuro-oncology, vol. 12 (5) , pp. 434–43, 2010.
  • 2009
    • M. Teyssot, A. Jarrousse, M. Manin, A. Chevry, S. Roche, F. Norre, C. Beaudoin, L. Morel, D. Boyer, R. Mahiou and A. Gautier, “Metal-NHC complexes: a survey of anti-cancer properties.”, Dalton trans., pp. 6894–902, 2009.
    • M. Teyssot, A. Jarrousse, A. Chevry, A. De Haze, C. Beaudoin, M. Manin, S. Nolan, S. Diez-Gonzalez, L. Morel and A. Gautier, “Toxicity of copper(I)-NHC complexes against human tumor cells: induction of cell cycle arrest, apoptosis, and DNA cleavage.”, Chemistry (Weinheim an der Bergstrasse, Germany), vol. 15 (2) , pp. 314–8, 2009.
    • C. Beaudoin, S. Maquaire, L. Leotoing, J. Allemand, C. Lours-Calet, G. Veyssiere, M. Manin and L. Morel, “[NPM: a new player in prostate cancer?].”, Med Sci (Paris), vol. 25 (1) , pp. 19–21, 2009.
  • 2007
    • L. Leotoing, L. Meunier, M. Manin, C. Mauduit, M. Decaussin, G. Verrijdt, F. Claessens, M. Benahmed, G. Veyssiere, L. Morel and C. Beaudoin, “Influence of nucleophosmin/B23 on DNA binding and transcriptional activity of the androgen receptor in prostate cancer cell.”, Oncogene, vol. 27 (20) , pp. 2858–67, 2007.